Hospital Inpatient Costs for Single Ventricle Patients Surviving the Fontan Procedure

Li Huang1, Chris Schilling1, Kim M Dalziel1

  • 1Centre for Health Policy, The University of Melbourne, Melbourne, VIC, Australia.

Insights

Fontan patients require significant inpatient resources throughout life, with over 40% of pediatric costs incurred after their final surgery. This highlights the long-term healthcare burden of single ventricle congenital heart disease.

Area of Science:

  • Pediatric Cardiology
  • Health Economics
  • Congenital Heart Disease

Background:

  • The Fontan procedure is a palliative surgery for single ventricle congenital heart disease.
  • Long-term inpatient resource utilization and associated costs for Fontan patients are not well-defined.
  • Understanding these costs is crucial for healthcare planning and resource allocation.

Purpose of the Study:

  • To estimate the inpatient resource use and costs for Fontan patients from birth to adulthood.
  • To identify factors influencing cost differences in Fontan patient care.
  • To analyze the distribution of costs across different stages of Fontan patient management.

Main Methods:

  • Linked inpatient costing records from four major Australian and New Zealand hospitals with Fontan patient data.
  • Utilized data from July 1995 to September 2014 for 420 Fontan patients.
  • Analyzed diagnoses including hypoplastic left heart syndrome, tricuspid atresia, and double inlet left ventricle.

Main Results:

  • The mean total inpatient cost from birth to 18 years was estimated at $390,601, with 164 inpatient days.
  • Costs during the staged procedures period (birth to Fontan completion) were $219,482 (82 days).
  • Post-Fontan costs over 15 years were $146,820 (65 days), with over 40% of pediatric costs occurring after the last planned surgery.

Conclusions:

  • Fontan patients represent a significant long-term inpatient resource demand.
  • Costs are influenced by factors such as sex and specific diagnoses like hypoplastic left heart syndrome.
  • A substantial portion of lifetime healthcare costs for Fontan patients arises in the post-palliative surgery phase.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
400
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
474